⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2911717 | 1.00 | — | — | |
| SCHEMBL6133105 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL6132602 | 0.98 | CNR2 (0.33) | — | |
| Hydrochloric Acid SCHEMBL3946346 | 0.98 | CNR2 (0.33) | — | |
| Hydrochloric Acid SCHEMBL3946341 | 0.98 | CNR2 (0.33) | — | |
| SCHEMBL29318365 | 0.85 | CNR2 (0.32) | — | |
| SCHEMBL19860656 | 0.85 | CNR2 (0.32) | — | |
| SCHEMBL27513197 | 0.84 | CNR2 (0.33) | — | |
| SCHEMBL27534264 | 0.84 | CNR2 (0.33) | — | |
| SCHEMBL30230325 | 0.83 | ALOX5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12583866-B2 | Pyrido[2,3-b][1,4]oxazines or tetrahydropyrido[2,3-b][1,4]oxazepines as IAP antagonists | BEONE MEDICINES I GMBH (CH) | 2026-03-24 | — | — | US | disclosed |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | BEIGENE, LTD. (KY) | 2025-01-14 | — | — | US | disclosed |
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230219975-A1 | PYRIDO[2,3-B][1,4]OXAZINES OR TETRAHYDROPYRIDO[2,3-B][1,4]OXAZEPINES AS IAP ANTAGONISTS | BEONE MEDICINES I GMBH (CH) | 2023-07-13 | — | — | US | disclosed |
| CN-116323565-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-10640516-B2 | Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines | PIQUR THERAPEUTICS AG (CH) | 2020-05-05 | — | — | US | disclosed |
| US-20190290653-A1 | TREATMENT OF SKIN LESIONS | TORQUR AG (CH) | 2019-09-26 | — | — | US | disclosed |
| US-20190284178-A1 | TREATMENT OF NEUROLOGICAL DISORDERS | TORQUR AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-20190031682-A1 | DIFLUOROMETHYL-AMINOPYRIDINES AND DIFLUOROMETHYL-AMINOPYRIMIDINES | TORQUR AG (CH) | 2019-01-31 | — | — | US | disclosed |
| US-9980973-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2018-05-29 | — | — | US | disclosed |
| US-20170224705-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2017-08-10 | — | — | US | disclosed |
| US-9617248-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2017-04-11 | — | — | US | disclosed |
| US-20150353537-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2015-12-10 | — | — | US | disclosed |
| WO-2013095275-A1 | NOVEL HEPATITIS C VIRUS INHIBITORS | MEDIVIR AB (SE) | 2013-06-27 | — | — | WO | disclosed |
| WO-2013010453-A1 | CHEMOKING RECEPTOR ANTAGONISTS | ABBOTT LABORATORIES (US) | 2013-01-24 | — | — | WO | disclosed |